

116TH CONGRESS  
1ST SESSION

# H. R. 4519

To amend the Public Health Service Act to authorize the Director of the National Institutes of Health to make awards to outstanding scientists, including physician-scientists, to support researchers focusing on pediatric research, including basic, clinical, translational, or pediatric pharmacological research, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 26, 2019

Mr. ENGEL (for himself and Mrs. RODGERS of Washington) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Public Health Service Act to authorize the Director of the National Institutes of Health to make awards to outstanding scientists, including physician-scientists, to support researchers focusing on pediatric research, including basic, clinical, translational, or pediatric pharmacological research, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Pediatricians Accel-  
5 erate Childhood Therapies Act of 2019” or the “PACT  
6 Act of 2019”.

1 **SEC. 2. TRANS-NIH AWARDS FOR EARLY-CAREER PEDI-**  
2 **ATRIC RESEARCHERS.**

3 Part G of title IV of the Public Health Service Act  
4 (42 U.S.C. 288 et seq.) is amended by adding at the end  
5 the following new section:

6 **“SEC. 489A. TRANS-NIH AWARDS FOR EARLY-CAREER PEDI-**  
7 **ATRIC RESEARCHERS.**

8 “(a) IN GENERAL.—The Director of the NIH shall  
9 make awards to outstanding scientists, including physi-  
10 cian-scientists, to support researchers focusing on pedi-  
11 atric research, including basic, clinical, translational, or  
12 pediatric pharmacological research.

13 “(b) PRIORITY RESEARCH TOPIC AREAS.—In car-  
14 rying out subsection (a), the Director of NIH, in consulta-  
15 tion with the Director of the Eunice Kennedy Shriver Na-  
16 tional Institute of Child Health and Human Development  
17 and the directors of other national research institutes and  
18 national centers that participate within the Trans-NIH  
19 Pediatric Research Consortium, shall—

20 “(1) establish priority research topic areas, in-  
21 formed by external stakeholders including research  
22 institutions, research societies, patient organizations,  
23 and industry; and

24 “(2) consider opportunities to align such pri-  
25 ority pediatric research topic areas with current and

1 future priorities of the National Institutes of Health,  
2 including—

3 “(A) childhood cancer;

4 “(B) precision medicine, genetics, and  
5 genomics;

6 “(C) rare diseases and disorders, such as  
7 sickle cell disease, and other diseases and dis-  
8 orders with significant unmet training needs;

9 “(D) fetal, placental, and neonatal develop-  
10 ment; and

11 “(E) child and adolescent mental health.

12 “(c) PRIORITY AWARDS.—In making awards under  
13 this section, the Director of NIH shall—

14 “(1) give priority to researchers, including phy-  
15 sician-scientists, who have a demonstrated pro-  
16 ficiency in conducting pediatric research, but have  
17 not yet achieved research independence at the time  
18 of their application; and

19 “(2) give special consideration to researchers  
20 from populations that are historically underrep-  
21 resented in pediatric medical research.

22 “(d) REQUIREMENTS.—The Director of NIH—

23 “(1) shall require recipients of awards under  
24 this section to use such awards to support pediatric  
25 research activities, including costs associated with

1 laboratory staff and other costs associated with the  
2 conduct of research; and

3 “(2) may allow recipients of awards under this  
4 section to use such awards for costs associated with  
5 receiving guidance and training from senior re-  
6 searchers as necessary to help such recipients reach  
7 a state of research independence, including con-  
8 ferences and other meeting participation.

9 “(e) SUPPLEMENT, NOT SUPPLANT.—Awards made  
10 under this section shall be used to supplement, and not  
11 supplant, other funding for research career development  
12 awards.”.

13 **SEC. 3. TRANS-NIH PEDIATRIC CONSORTIUM.**

14 Title IV of the Public Health Service is amended by  
15 inserting after section 409D (42 U.S.C. 284h) the fol-  
16 lowing new section:

17 **“SEC. 409D-1. TRANS-NIH PEDIATRIC CONSORTIUM.**

18 “(a) ESTABLISHMENT.—The Director of NIH shall  
19 establish and maintain a consortium to be known as the  
20 Trans-NIH Pediatric Research Consortium (in this sec-  
21 tions referred to as the ‘Consortium’) to coordinate pedi-  
22 atric research programs across the National Institutes of  
23 Health.

1           “(b) MEMBERSHIP.—The members of the Consor-  
2     tium shall consist of representatives of multiple national  
3     research institutes and national centers.

4           “(c) CHAIR.—The Chair of the Consortium shall be  
5     the Director of the Eunice Kennedy Shriver National In-  
6     stitute of Child Health and Human Development (or the  
7     Director’s designee).

8           “(d) DUTIES.—In coordinating pediatric research  
9     programs across the National Institutes of Health, the  
10    Consortium shall—

11                   “(1) establish pediatric research priorities;

12                   “(2) identify gaps and opportunities for re-  
13     search collaborations involving multiple national re-  
14     search institutes and national centers; and

15                   “(3) identify opportunities to develop the next  
16     generation of pediatric researchers.

17           “(e) CONSULTATION.—The Consortium shall consult  
18     regularly with external experts in the field of pediatric re-  
19     search, including children’s hospitals, children’s research  
20     institutions, patient organizations, and other stake-  
21     holders.”.

○